Diagnosis and therapy of multiple myeloma.
10.3904/kjim.2013.28.3.263
- Author:
Antonio PALUMBO
1
;
Chiara CERRATO
Author Information
1. Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliera Citta della Salute e della Scienza di Torino, Torino, Italy. appalumbo@yahoo.com
- Publication Type:Review
- Keywords:
Multiple myeloma;
Thalidomide;
Lenalidomide;
Bortezomib;
Induction therapy
- MeSH:
Age Factors;
Antineoplastic Agents/therapeutic use;
Boronic Acids/therapeutic use;
Humans;
Immunologic Factors/therapeutic use;
Multiple Myeloma/diagnosis/epidemiology/*therapy;
Prognosis;
Pyrazines/therapeutic use;
Stem Cell Transplantation;
Thalidomide/analogs & derivatives/therapeutic use
- From:The Korean Journal of Internal Medicine
2013;28(3):263-273
- CountryRepublic of Korea
- Language:English
-
Abstract:
Many advances in the treatment of multiple myeloma have been made due to the use of transplantation and the introduction of novel agents including thalidomide, lenalidomide, and bortezomib. The first step is recognizing the symptoms and starting prompt treatment. Different strategies should be selected for young and elderly subjects. Young patients are commonly eligible for transplantation, which is now considered the standard approach for this setting, and various inductions therapies containing novel agents are available before transplantation. Elderly patients are usually not eligible for transplantation, and gentler approaches with new drugs combinations are used for their treatment.
